Literature DB >> 22733579

Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis.

Anna L Paterson1, Maria O'Donovan, Elena Provenzano, Liam J Murray, Helen G Coleman, Brian T Johnson, Damian T McManus, Marco Novelli, Laurence B Lovat, Rebecca C Fitzgerald.   

Abstract

Despite being common in epithelial malignancies, the timing of receptor tyrosine kinase (RTK) up-regulation is poorly understood and therefore hampers the identification of the receptor to target for effective treatment. We aimed to determine if RTK expression changes were early events in carcinogenesis. Oesophageal adenocarcinoma and its pre-invasive lesion, Barrett's oesophagus, were used for immunohistochemical analysis of the RTK panel, EGFR, ErbB2, ErbB3, Met, and FGFR2, by utilizing a cohort of patients with invasive disease (n = 367) and two cohorts with pre-invasive disease, one cross-sectional (n = 110) and one longitudinal in time (n = 91). The results demonstrated that 51% of oesophageal adenocarcinomas overexpressed at least one of the RTK panel, with 21% of these overexpressing multiple receptors. Up-regulation of RTK expression was an early event corresponding with low-grade dysplasia development (25% in areas without dysplasia versus 63% in low-grade dysplasia, p < 0.001). There was a trend for an increase in the prevalence of concomitant overexpression of multiple receptors as intestinal metaplasia progressed to low-grade dysplasia, 7% versus 10%; and from low-grade dysplasia to high-grade dysplasia, 10% versus 19% (p = 0.06 and 0.24, respectively). The timing of receptor up-regulation varied; FGFR, ErbB2, and Met overexpression occurred as dysplasia first developed, whilst EGFR overexpression was predominately seen in invasive disease and ErbB3 overexpression was uniformly rare. We provide evidence for a frequent and early role for multiple different RTKs in oesophageal carcinogenesis. Given the early timing of receptor deregulation, inhibiting RTKs in pre-invasive disease may also represent a novel and effective chemopreventive strategy.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22733579     DOI: 10.1002/path.4044

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

Review 1.  [Update on Barrett esophagus and Barrett carcinoma].

Authors:  M Werner; S Laßmann
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 2.  Molecular markers and imaging tools to identify malignant potential in Barrett's esophagus.

Authors:  Michael Bennett; Hiroshi Mashimo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

Review 3.  Sticking to the Problem: Engineering Adhesion in Molecular Endoscopic Imaging.

Authors:  Mahboubeh S Noori; Sarah J Bodle; Christian A Showalter; Evan S Streator; David S Drozek; Monica M Burdick; Douglas J Goetz
Journal:  Cell Mol Bioeng       Date:  2020-01-21       Impact factor: 2.321

4.  Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma.

Authors:  Haixing Wang; Dongxian Jiang; Qi Song; Chen Xu; Yuan Shi; Xiaojing Li; Jie Huang; Yifan Xu; Akesu Sujie; Haiying Zeng; Yunshi Zhong; Lijie Tan; Yingyong Hou
Journal:  Tumour Biol       Date:  2016-01-25

Review 5.  Oesophageal cancer.

Authors:  Elizabeth C Smyth; Jesper Lagergren; Rebecca C Fitzgerald; Florian Lordick; Manish A Shah; Pernilla Lagergren; David Cunningham
Journal:  Nat Rev Dis Primers       Date:  2017-07-27       Impact factor: 52.329

Review 6.  The Evolving Genomic Landscape of Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Gianmarco Contino; Thomas L Vaughan; David Whiteman; Rebecca C Fitzgerald
Journal:  Gastroenterology       Date:  2017-07-14       Impact factor: 22.682

Review 7.  Biomarkers for dysplastic Barrett's: ready for prime time?

Authors:  Eleanor M Gregson; Rebecca C Fitzgerald
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

Review 8.  HER2-targeted therapies - a role beyond breast cancer.

Authors:  Do-Youn Oh; Yung-Jue Bang
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675

9.  Multiplexed Targeting of Barrett's Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo.

Authors:  Jing Chen; Juan Zhou; Zhenghong Gao; Xue Li; Fa Wang; Xiyu Duan; Gaoming Li; Bishnu P Joshi; Rork Kuick; Henry D Appelman; Thomas D Wang
Journal:  J Med Chem       Date:  2018-06-19       Impact factor: 7.446

10.  Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.

Authors:  Michaela Aichler; Martin Motschmann; Uta Jütting; Birgit Luber; Karen Becker; Katja Ott; Florian Lordick; Rupert Langer; Marcus Feith; Jörg Rüdiger Siewert; Axel Walch
Journal:  Oncotarget       Date:  2014-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.